Načítá se...
The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells
About 20% of breast cancers are characterized by amplification and overexpression of the HER2 oncogene. Although significant progress has been achieved for treating such patients with HER2 inhibitor trastuzumab, more than half of the patients respond poorly or become resistant to the treatment. Sinc...
Uloženo v:
| Vydáno v: | Mol Oncol |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2012
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5528495/ https://ncbi.nlm.nih.gov/pubmed/23253899 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2012.10.012 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|